ID   ROCK2_RAT               Reviewed;        1388 AA.
AC   Q62868;
DT   24-MAY-2004, integrated into UniProtKB/Swiss-Prot.
DT   21-SEP-2011, sequence version 2.
DT   02-OCT-2024, entry version 195.
DE   RecName: Full=Rho-associated protein kinase 2;
DE            EC=2.7.11.1;
DE   AltName: Full=Rho-associated, coiled-coil-containing protein kinase 2;
DE   AltName: Full=Rho-associated, coiled-coil-containing protein kinase II;
DE            Short=ROCK-II;
DE   AltName: Full=RhoA-binding kinase 2;
DE   AltName: Full=p150 ROK-alpha;
DE            Short=ROKalpha;
DE   AltName: Full=p164 ROCK-2;
GN   Name=Rock2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AUTOPHOSPHORYLATION, INTERACTION WITH
RP   RHOA, AND SUBCELLULAR LOCATION.
RC   TISSUE=Brain;
RX   PubMed=7493923; DOI=10.1074/jbc.270.49.29051;
RA   Leung T., Manser E., Tan L., Lim L.;
RT   "A novel serine/threonine kinase binding the Ras-related RhoA GTPase which
RT   translocates the kinase to peripheral membranes.";
RL   J. Biol. Chem. 270:29051-29054(1995).
RN   [2]
RP   FUNCTION, AUTOPHOSPHORYLATION, INTERACTION WITH RHOA; RHOB AND RHOC,
RP   MUTAGENESIS OF LYS-121, AND TISSUE SPECIFICITY.
RX   PubMed=8816443; DOI=10.1128/mcb.16.10.5313;
RA   Leung T., Chen X.-Q., Manser E., Lim L.;
RT   "The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and
RT   is involved in the reorganization of the cytoskeleton.";
RL   Mol. Cell. Biol. 16:5313-5327(1996).
RN   [3]
RP   FUNCTION, ROLE IN HYPERTENSION, AND INHIBITION BY Y-27632.
RX   PubMed=9353125; DOI=10.1038/40187;
RA   Uehata M., Ishizaki T., Satoh H., Ono T., Kawahara T., Morishita T.,
RA   Tamakawa H., Yamagami K., Inui J., Maekawa M., Narumiya S.;
RT   "Calcium sensitization of smooth muscle mediated by a Rho-associated
RT   protein kinase in hypertension.";
RL   Nature 389:990-994(1997).
RN   [4]
RP   INTERACTION WITH IRS1.
RX   PubMed=11739394; DOI=10.1074/jbc.m110508200;
RA   Begum N., Sandu O.A., Ito M., Lohmann S.M., Smolenski A.;
RT   "Active Rho kinase (ROK-alpha) associates with insulin receptor substrate-1
RT   and inhibits insulin signaling in vascular smooth muscle cells.";
RL   J. Biol. Chem. 277:6214-6222(2002).
RN   [5]
RP   INTERACTION WITH RAF1.
RX   PubMed=15753127; DOI=10.1083/jcb.200409162;
RA   Ehrenreiter K., Piazzolla D., Velamoor V., Sobczak I., Small J.V.,
RA   Takeda J., Leung T., Baccarini M.;
RT   "Raf-1 regulates Rho signaling and cell migration.";
RL   J. Cell Biol. 168:955-964(2005).
RN   [6]
RP   CLEAVAGE BY GRANZYME B.
RX   PubMed=15699075; DOI=10.1084/jem.20031877;
RA   Sebbagh M., Hamelin J., Bertoglio J., Solary E., Breard J.;
RT   "Direct cleavage of ROCK II by granzyme B induces target cell membrane
RT   blebbing in a caspase-independent manner.";
RL   J. Exp. Med. 201:465-471(2005).
RN   [7]
RP   DOMAIN, PHOSPHORYLATION AT THR-414, AND MUTAGENESIS OF ASP-48; LYS-121;
RP   THR-414 AND TRP-1170.
RX   PubMed=19099536; DOI=10.1042/bj20081376;
RA   Couzens A.L., Saridakis V., Scheid M.P.;
RT   "The hydrophobic motif of ROCK2 requires association with the N-terminal
RT   extension for kinase activity.";
RL   Biochem. J. 419:141-148(2009).
RN   [8]
RP   FUNCTION, INTERACTION WITH PPP1R12A, AND SUBCELLULAR LOCATION.
RX   PubMed=19131646; DOI=10.1161/circresaha.108.188524;
RA   Wang Y., Zheng X.R., Riddick N., Bryden M., Baur W., Zhang X., Surks H.K.;
RT   "ROCK isoform regulation of myosin phosphatase and contractility in
RT   vascular smooth muscle cells.";
RL   Circ. Res. 104:531-540(2009).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF MYL9/MLC2 AND PPP1R12A.
RX   PubMed=21457715; DOI=10.1016/j.febslet.2011.03.054;
RA   Tan I., Lai J., Yong J., Li S.F., Leung T.;
RT   "Chelerythrine perturbs lamellar actomyosin filaments by selective
RT   inhibition of myotonic dystrophy kinase-related Cdc42-binding kinase.";
RL   FEBS Lett. 585:1260-1268(2011).
CC   -!- FUNCTION: Protein kinase which is a key regulator of actin cytoskeleton
CC       and cell polarity. Involved in regulation of smooth muscle contraction,
CC       actin cytoskeleton organization, stress fiber and focal adhesion
CC       formation, neurite retraction, cell adhesion and motility via
CC       phosphorylation of ADD1, BRCA2, CNN1, EZR, DPYSL2, EP300, MSN,
CC       MYL9/MLC2, NPM1, RDX, PPP1R12A and VIM. Phosphorylates SORL1 and IRF4.
CC       Acts as a negative regulator of VEGF-induced angiogenic endothelial
CC       cell activation. Positively regulates the activation of p42/MAPK1-
CC       p44/MAPK3 and of p90RSK/RPS6KA1 during myogenic differentiation. Plays
CC       an important role in the timely initiation of centrosome duplication.
CC       Inhibits keratinocyte terminal differentiation. May regulate closure of
CC       the eyelids and ventral body wall through organization of actomyosin
CC       bundles. Plays a critical role in the regulation of spine and synaptic
CC       properties in the hippocampus. Plays a role in placental homeostasis
CC       during the perinatal period. Plays an important role in generating the
CC       circadian rhythm of the aortic myofilament Ca(2+) sensitivity and
CC       vascular contractility by modulating the myosin light chain
CC       phosphorylation. {ECO:0000269|PubMed:19131646,
CC       ECO:0000269|PubMed:21457715, ECO:0000269|PubMed:7493923,
CC       ECO:0000269|PubMed:8816443, ECO:0000269|PubMed:9353125}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Activated by RHOA binding. Inhibited by Y-27632.
CC   -!- SUBUNIT: Homodimer (By similarity). Interacts with IRS1
CC       (PubMed:11739394). Interacts with RAF1 (PubMed:15753127). Interacts
CC       with RHOA (activated by GTP), RHOB, RHOC (PubMed:7493923,
CC       PubMed:8816443). Interacts with PPP1R12A (PubMed:19131646). Interacts
CC       with EP300 (By similarity). Interacts with CHORDC1 (By similarity).
CC       Interacts with BRCA2 (By similarity). Interacts with NPM1; this
CC       interaction enhances its activity (By similarity). Interacts with SORL1
CC       (By similarity). Interacts with PJVK (By similarity).
CC       {ECO:0000250|UniProtKB:O75116, ECO:0000250|UniProtKB:P70336,
CC       ECO:0000250|UniProtKB:Q28021, ECO:0000269|PubMed:11739394,
CC       ECO:0000269|PubMed:15753127, ECO:0000269|PubMed:19131646,
CC       ECO:0000269|PubMed:7493923, ECO:0000269|PubMed:8816443}.
CC   -!- INTERACTION:
CC       Q62868; P19105: MYL12A; Xeno; NbExp=2; IntAct=EBI-1569209, EBI-354418;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane; Peripheral membrane
CC       protein. Nucleus {ECO:0000250}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000250}. Note=Cytoplasmic, and
CC       associated with actin microfilaments and the plasma membrane.
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain, lung, liver, skeletal
CC       muscle, kidney and testis. {ECO:0000269|PubMed:8816443}.
CC   -!- DOMAIN: An interaction between Thr-414 and Asp-48 is essential for
CC       kinase activity and dimerization. {ECO:0000269|PubMed:19099536}.
CC   -!- PTM: Autophosphorylated. Phosphorylation at Tyr-722 reduces its binding
CC       to RHOA and is crucial for focal adhesion dynamics. Dephosphorylation
CC       by PTPN11 stimulates its RHOA binding activity (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Cleaved by granzyme B during apoptosis. This leads to constitutive
CC       activation of the kinase and membrane blebbing.
CC   -!- DISEASE: Note=May play a role in hypertension. ROCK-inhibitors lower
CC       the blood pressure in spontaneous hypertensive, renal hypertensive and
CC       deoxycorticosterone acetate-induced hypertensive rats, but not in
CC       normal rats.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB37540.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U38481; AAB37540.1; ALT_INIT; mRNA.
DR   RefSeq; NP_037154.2; NM_013022.2.
DR   PDB; 2ROV; NMR; -; A=1151-1351.
DR   PDB; 2ROW; NMR; -; A=1237-1320.
DR   PDBsum; 2ROV; -.
DR   PDBsum; 2ROW; -.
DR   AlphaFoldDB; Q62868; -.
DR   SMR; Q62868; -.
DR   BioGRID; 247569; 3.
DR   IntAct; Q62868; 5.
DR   MINT; Q62868; -.
DR   STRING; 10116.ENSRNOP00000073496; -.
DR   BindingDB; Q62868; -.
DR   ChEMBL; CHEMBL5490; -.
DR   DrugCentral; Q62868; -.
DR   GuidetoPHARMACOLOGY; 1504; -.
DR   iPTMnet; Q62868; -.
DR   PhosphoSitePlus; Q62868; -.
DR   jPOST; Q62868; -.
DR   PaxDb; 10116-ENSRNOP00000006403; -.
DR   GeneID; 25537; -.
DR   KEGG; rno:25537; -.
DR   AGR; RGD:3590; -.
DR   CTD; 9475; -.
DR   RGD; 3590; Rock2.
DR   eggNOG; KOG0612; Eukaryota.
DR   InParanoid; Q62868; -.
DR   OrthoDB; 4221785at2759; -.
DR   Reactome; R-RNO-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-RNO-416482; G alpha (12/13) signalling events.
DR   Reactome; R-RNO-416572; Sema4D induced cell migration and growth-cone collapse.
DR   Reactome; R-RNO-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-RNO-5627117; RHO GTPases Activate ROCKs.
DR   Reactome; R-RNO-8980692; RHOA GTPase cycle.
DR   Reactome; R-RNO-9013026; RHOB GTPase cycle.
DR   Reactome; R-RNO-9013407; RHOH GTPase cycle.
DR   Reactome; R-RNO-9013422; RHOBTB1 GTPase cycle.
DR   EvolutionaryTrace; Q62868; -.
DR   PRO; PR:Q62868; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005813; C:centrosome; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; ISO:RGD.
DR   GO; GO:0005856; C:cytoskeleton; IBA:GO_Central.
DR   GO; GO:0098978; C:glutamatergic synapse; ISO:RGD.
DR   GO; GO:0031594; C:neuromuscular junction; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0014069; C:postsynaptic density; ISO:RGD.
DR   GO; GO:0048786; C:presynaptic active zone; ISO:RGD.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; ISO:RGD.
DR   GO; GO:0031616; C:spindle pole centrosome; ISO:RGD.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0061133; F:endopeptidase activator activity; ISO:RGD.
DR   GO; GO:0016301; F:kinase activity; TAS:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0002020; F:protease binding; ISO:RGD.
DR   GO; GO:0004672; F:protein kinase activity; ISO:RGD.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISO:RGD.
DR   GO; GO:0072518; F:Rho-dependent protein serine/threonine kinase activity; ISO:RGD.
DR   GO; GO:0031267; F:small GTPase binding; IEA:InterPro.
DR   GO; GO:0030036; P:actin cytoskeleton organization; ISO:RGD.
DR   GO; GO:0031032; P:actomyosin structure organization; IBA:GO_Central.
DR   GO; GO:0097746; P:blood vessel diameter maintenance; ISO:RGD.
DR   GO; GO:0007249; P:canonical NF-kappaB signal transduction; ISO:RGD.
DR   GO; GO:1905145; P:cellular response to acetylcholine; ISO:RGD.
DR   GO; GO:0071394; P:cellular response to testosterone stimulus; ISO:RGD.
DR   GO; GO:0051298; P:centrosome duplication; ISO:RGD.
DR   GO; GO:0030261; P:chromosome condensation; TAS:RGD.
DR   GO; GO:0030866; P:cortical actin cytoskeleton organization; ISO:RGD.
DR   GO; GO:0048813; P:dendrite morphogenesis; ISO:RGD.
DR   GO; GO:0048598; P:embryonic morphogenesis; IBA:GO_Central.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; ISO:RGD.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; ISO:RGD.
DR   GO; GO:0000281; P:mitotic cytokinesis; IBA:GO_Central.
DR   GO; GO:0061157; P:mRNA destabilization; ISO:RGD.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; ISO:RGD.
DR   GO; GO:1903347; P:negative regulation of bicellular tight junction assembly; ISO:RGD.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISO:RGD.
DR   GO; GO:0045019; P:negative regulation of nitric oxide biosynthetic process; ISO:RGD.
DR   GO; GO:0150033; P:negative regulation of protein localization to lysosome; ISO:RGD.
DR   GO; GO:0001843; P:neural tube closure; ISO:RGD.
DR   GO; GO:1902993; P:positive regulation of amyloid precursor protein catabolic process; ISO:RGD.
DR   GO; GO:1902004; P:positive regulation of amyloid-beta formation; ISO:RGD.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; IMP:ARUK-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISO:RGD.
DR   GO; GO:0010825; P:positive regulation of centrosome duplication; ISO:RGD.
DR   GO; GO:0032723; P:positive regulation of connective tissue growth factor production; IMP:ARUK-UCL.
DR   GO; GO:1905205; P:positive regulation of connective tissue replacement; IMP:ARUK-UCL.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; ISO:RGD.
DR   GO; GO:0090271; P:positive regulation of fibroblast growth factor production; IMP:ARUK-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:ARUK-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISO:RGD.
DR   GO; GO:1902966; P:positive regulation of protein localization to early endosome; ISO:RGD.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISO:RGD.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; ISO:RGD.
DR   GO; GO:0098974; P:postsynaptic actin cytoskeleton organization; ISO:RGD.
DR   GO; GO:0072659; P:protein localization to plasma membrane; ISO:RGD.
DR   GO; GO:0110061; P:regulation of angiotensin-activated signaling pathway; ISO:RGD.
DR   GO; GO:1901888; P:regulation of cell junction assembly; IBA:GO_Central.
DR   GO; GO:1900037; P:regulation of cellular response to hypoxia; ISO:RGD.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:1903140; P:regulation of establishment of endothelial barrier; ISO:RGD.
DR   GO; GO:0045616; P:regulation of keratinocyte differentiation; ISO:RGD.
DR   GO; GO:0031644; P:regulation of nervous system process; ISO:RGD.
DR   GO; GO:0051246; P:regulation of protein metabolic process; ISO:RGD.
DR   GO; GO:0090128; P:regulation of synapse maturation; ISO:RGD.
DR   GO; GO:1990776; P:response to angiotensin; ISO:RGD.
DR   GO; GO:0002931; P:response to ischemia; ISO:RGD.
DR   GO; GO:0071559; P:response to transforming growth factor beta; IGI:ARUK-UCL.
DR   GO; GO:0007266; P:Rho protein signal transduction; IMP:MGI.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0006939; P:smooth muscle contraction; IEA:InterPro.
DR   CDD; cd20875; C1_ROCK2; 1.
DR   CDD; cd11638; HR1_ROCK2; 1.
DR   CDD; cd01242; PH_ROCK; 1.
DR   CDD; cd22250; ROCK_SBD; 1.
DR   CDD; cd05621; STKc_ROCK2; 1.
DR   Gene3D; 1.20.5.340; -; 1.
DR   Gene3D; 3.30.60.20; -; 1.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 2.
DR   Gene3D; 1.20.5.730; Single helix bin; 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR046349; C1-like_sf.
DR   InterPro; IPR011072; HR1_rho-bd.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR050839; Rho-assoc_Ser/Thr_Kinase.
DR   InterPro; IPR020684; ROCK1/ROCK2.
DR   InterPro; IPR029878; ROCK2_cat.
DR   InterPro; IPR037311; ROCK2_HR1.
DR   InterPro; IPR015008; ROCK_Rho-bd_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR22988; MYOTONIC DYSTROPHY S/T KINASE-RELATED; 1.
DR   PANTHER; PTHR22988:SF28; RHO-ASSOCIATED PROTEIN KINASE 2; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF08912; Rho_Binding; 1.
DR   PIRSF; PIRSF037568; Rho_kinase; 1.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF57889; Cysteine-rich domain; 1.
DR   SUPFAM; SSF103652; G protein-binding domain; 1.
DR   SUPFAM; SSF50729; PH domain-like; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS51860; REM_1; 1.
DR   PROSITE; PS51859; RHO_BD; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Biological rhythms; Cell membrane; Coiled coil;
KW   Cytoplasm; Cytoskeleton; Kinase; Magnesium; Membrane; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   CHAIN           1..1388
FT                   /note="Rho-associated protein kinase 2"
FT                   /id="PRO_0000086627"
FT   DOMAIN          92..354
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          357..425
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   DOMAIN          497..573
FT                   /note="REM-1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01207"
FT   DOMAIN          979..1047
FT                   /note="RhoBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01206"
FT   DOMAIN          1150..1349
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   ZN_FING         1260..1315
FT                   /note="Phorbol-ester/DAG-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   REGION          1..24
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          363..784
FT                   /note="Interaction with PPP1R12A"
FT                   /evidence="ECO:0000269|PubMed:19131646"
FT   REGION          373..420
FT                   /note="Interaction with NPM1"
FT                   /evidence="ECO:0000250"
FT   REGION          513..532
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          979..1047
FT                   /note="RHOA binding"
FT                   /evidence="ECO:0000250"
FT   REGION          1345..1388
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          439..1024
FT                   /evidence="ECO:0000255"
FT   COILED          1052..1131
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        1363..1388
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        214
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         98..106
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         121
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            1131..1132
FT                   /note="Cleavage; by granzyme B"
FT   MOD_RES         414
FT                   /note="Phosphothreonine; by ROCK2"
FT                   /evidence="ECO:0000269|PubMed:19099536"
FT   MOD_RES         722
FT                   /note="Phosphotyrosine; by SRC"
FT                   /evidence="ECO:0000250|UniProtKB:O75116"
FT   MOD_RES         1137
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O75116"
FT   MOD_RES         1212
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:O75116"
FT   MOD_RES         1362
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O75116"
FT   MOD_RES         1374
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O75116"
FT   MUTAGEN         48
FT                   /note="D->A: Loss of kinase activity; autophosphorylation
FT                   and dimerization."
FT                   /evidence="ECO:0000269|PubMed:19099536"
FT   MUTAGEN         121
FT                   /note="K->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:19099536,
FT                   ECO:0000269|PubMed:8816443"
FT   MUTAGEN         121
FT                   /note="K->M: Loss of autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:19099536,
FT                   ECO:0000269|PubMed:8816443"
FT   MUTAGEN         414
FT                   /note="T->A: Loss of kinase activity; autophosphorylation
FT                   and dimerization."
FT                   /evidence="ECO:0000269|PubMed:19099536"
FT   MUTAGEN         1170
FT                   /note="W->A: Increased activity and autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:19099536"
FT   STRAND          1153..1158
FT                   /evidence="ECO:0007829|PDB:2ROV"
FT   STRAND          1163..1166
FT                   /evidence="ECO:0007829|PDB:2ROV"
FT   STRAND          1172..1178
FT                   /evidence="ECO:0007829|PDB:2ROV"
FT   STRAND          1181..1186
FT                   /evidence="ECO:0007829|PDB:2ROV"
FT   HELIX           1188..1192
FT                   /evidence="ECO:0007829|PDB:2ROV"
FT   STRAND          1197..1200
FT                   /evidence="ECO:0007829|PDB:2ROV"
FT   HELIX           1202..1204
FT                   /evidence="ECO:0007829|PDB:2ROV"
FT   STRAND          1205..1210
FT                   /evidence="ECO:0007829|PDB:2ROV"
FT   TURN            1213..1215
FT                   /evidence="ECO:0007829|PDB:2ROV"
FT   STRAND          1217..1219
FT                   /evidence="ECO:0007829|PDB:2ROV"
FT   TURN            1221..1223
FT                   /evidence="ECO:0007829|PDB:2ROV"
FT   HELIX           1224..1226
FT                   /evidence="ECO:0007829|PDB:2ROV"
FT   STRAND          1227..1232
FT                   /evidence="ECO:0007829|PDB:2ROV"
FT   STRAND          1234..1236
FT                   /evidence="ECO:0007829|PDB:2ROV"
FT   STRAND          1256..1258
FT                   /evidence="ECO:0007829|PDB:2ROW"
FT   STRAND          1261..1266
FT                   /evidence="ECO:0007829|PDB:2ROW"
FT   STRAND          1275..1281
FT                   /evidence="ECO:0007829|PDB:2ROW"
FT   STRAND          1284..1286
FT                   /evidence="ECO:0007829|PDB:2ROW"
FT   STRAND          1290..1296
FT                   /evidence="ECO:0007829|PDB:2ROW"
FT   STRAND          1299..1301
FT                   /evidence="ECO:0007829|PDB:2ROW"
FT   HELIX           1302..1307
FT                   /evidence="ECO:0007829|PDB:2ROW"
FT   TURN            1317..1319
FT                   /evidence="ECO:0007829|PDB:2ROW"
FT   STRAND          1325..1330
FT                   /evidence="ECO:0007829|PDB:2ROV"
FT   HELIX           1334..1347
FT                   /evidence="ECO:0007829|PDB:2ROV"
SQ   SEQUENCE   1388 AA;  160387 MW;  B23672CA8645067C CRC64;
     MSRPPPTGKM PGAPEAAAGD GAGAGRQRKL EALIRDPRSP INVESLLDGL NSLVLDLDFP
     ALRKNKNIDN FLNRYEKIVK KIRGLQMKAE DYDVVKVIGR GAFGEVQLVR HKASQKVYAM
     KLLSKFEMIK RSDSAFFWEE RDIMAFANSP WVVQLFCAFQ DDRYLYMVME YMPGGDLVNL
     MSNYDVPEKW AKFYTAEVVL ALDAIHSMGL IHRDVKPDNM LLDKHGHLKL ADFGTCMKMD
     ETGMVHCDTA VGTPDYISPE VLKSQGGDGY YGRECDWWSV GVFLFEMLVG DTPFYADSLV
     GTYSKIMDHK NSLCFPEDTE ISKHAKNLIC AFLTDREVRL GRNGVEEIKS ASFFKNDQWN
     WDNIRETAAP VVPELSSDID SSNFDDIEDD KGDVETFPIP KAFVGNQLPF IGFTYFRENL
     LLSDSPPCRE NDAIQTRKSE ESQEIQKKLY ALEEHLSSEV QAKEELEQKC KSINTRLEKT
     AKELEEEITF RKNVESTLRQ LEREKALLQH KNAEYQRKAD HEADKKRNLE NDVNSLKDQL
     EDLKKRNQSS QISTEKVNQL QKQLDEANAL LRTESDTAAR LRKTQAESSK QIQQLESNNR
     DLQDKNCLLE TAKLKLEKEF INLQSALESE RRDRTHGSEI INDLQGRISG LEEDLKTGKT
     LLAKVELEKR QLQEKLTDLE KEKSNMEIDM TYQLKVIQQS LEQEEAEHKT TKARLADKNK
     IYESIEEAKS EAMKEMEKKL LEERSLKQKV ENLLLEAEKR CSILDCDLKQ SQQKLNELLK
     QKDVLNEDVR NLTLKIEQET QKRCLMQNDL KMQTQQVNTL KMSEKQIKQE NNHLMEMKMN
     LEKQNAELRK ERQDADGQMK ELQDQLEAEQ YFSTLYKTQV RELKEENEEK TKLCKELQQK
     KQDLQDERDS LAAQLEITLT KADSEQLARS IAEEQYSDLE KEKIMKELEI KEMMARHKQE
     LTEKDATIAS LEETNRTLTS DVANLANEKE ELNNKLKDTQ EQLSKLKDEE ISAAAIKAQF
     EKQLLTERTL KTQAVNKLAE IMNRKEPVKR GSDTDVRRKE KENRKLHMEL KSEREKLTQQ
     MIKYQKELNE MQAQIAEESQ IRIELQMTLD SKDSDIEQLR SQLQALHIGM DSSSIGSGPG
     DAEPDDGFPE SRLEGWLSLP VRNNTKKFGW VKKYVIVSSK KILFYDSEQD KEQSNPYMVL
     DIDKLFHVRP VTQTDVYRAD AKEIPRIFQI LYANEGESKK EPEFPVEPVG EKSNYICHKG
     HEFIPTLYHF PTNCEACMKP LWHMFKPPPA LECSRCHIKC HKDHMDKKEE IIAPCKVYYD
     ISSAKNLLLL ANSTEEQQKW VSRLVKKIPK KPPAPDPFAR SSPRTSMKIQ QNQSIRRPSR
     QLAPNKPS
//
